Figure 2.
Diabetes diagnoses per 100 patient-years for (a) rs11086926 and (b) rs11868513 for each genotype group within each treatment arm. (a) The GG homozygotes of rs11086926 had a differential response to lifestyle and metformin (rs11086926 × metformin vs placebo, Pinteraction = 0.002). The GG carriers in the lifestyle group had a significantly lower diabetes incidence than did carriers of the same genotype in the placebo (P = 0.007) and metformin (P = 0.006) groups. These GG homozygotes had no response to metformin therapy compared with placebo (P = 0.8). (b) There was a significant treatment × genotype interaction for rs1186513. rs11868513 × metformin vs placeb, Pinteraction = 0.0007, and rs11868513 × lifestyle vs placebo Pinteraction = 0.03. The AA genotype of rs11868513, despite having a higher diabetes risk in the placebo group, had a dramatic response to metformin (P = 0.008) and lifestyle (P = 0.001) therapy. The AG genotype also demonstrated a decrease to both lifestyle (P < 0.001) and metformin (P = 0.002) therapy compared with placebo. The GG genotype carriers showed a decrease in diabetes incidence to lifestyle intervention (P < 0.001) and no response to metformin (P = 0.2) compared with placebo.